EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

An Inverse Agonist of Estrogen-Related Receptor Gamma, GSK5182, Enhances Na+/I− Symporter Function in Radioiodine-Refractory Papillary Thyroid Cancer Cells

Thoudam Debraj Singh, Jae Eon Lee, Kwang Hee Son, Bo Ra Lee, Sang Kyoon Kim, Deepak Gulwani, Vijaya Sarangthem iD, Yong Hyun Jeon

Cells · 2023

DOI: 10.3390/cells12030470 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, 2023. Verfasst von Thoudam Debraj Singh und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology Lab, All India Institute of Medical Sciences (AIIMS), New Delhi 110029, India. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Symporters. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science & Engineering Research Board (SERB), India, Department of Health Research (DHR), India, Intramural Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Previously, we reported that an inverse agonist of estrogen-related receptor gamma (ERRγ), GSK5182, enhances sodium iodide (Na+/I−) symporter (NIS) function through mitogen-activated protein (MAP) kinase signaling in anaplastic thyroid cancer cells. This finding helped us to further investigate the effects of GSK5182 on NIS function in papillary thyroid cancer (PTC) refractory to radioactive iodine (RAI) therapy. Herein, we report the effects of ERRγ on the regulation of NIS function in RAI-resistant PTC cells using GSK5182. RAI-refractory BCPAP cells were treated with GK5182 for 24 h at various concentrations, and radioiodine avidity was determined with or without potassium perchlorate (KClO4) as an NIS inhibitor. We explored the effects of GSK5182 on ERRγ, the mitogen-activated protein (MAP) kinase pathway, and iodide metabolism-related genes. We examined whether the MAP pathway affected GSK5182-mediated NIS function using U0126, a selective MEK inhibitor. A clonogenic assay was performed to evaluate the cytotoxic effects of I-131. GSK5182 induced an increase in radioiodine avidity in a dose-dependent manner, and the enhanced uptake was completely inhibited by KClO4 in BCPAP cells. We found that ERRγ was downregulated and phosphorylated extracellular signal-regulated kinase (ERK)1/2 was upregulated in BCPAP cells, with an increase in total and membranous NIS and iodide metabolism-related genes. MEK inhibitors reversed the increase in radioiodine avidity induced by GSK5182. Clonogenic examination revealed the lowest survival in cells treated with a combination of GSK5182 and I-131 compared to those treated with either GSK518 or I-131 alone. We demonstrate that an inverse agonist of ERRγ, GSK5182, enhances the function of NIS protein via the modulation of ERRγ and MAP kinase signaling, thereby leading to increased responsiveness to radioiodine in RAI-refractory papillary thyroid cancer cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid NeoplasmsSymportersHumansIodine RadioisotopesThyroid Cancer, PapillaryIodidesDrug Inverse AgonismMitogensMitogen-Activated Protein KinasesMitogen-Activated Protein Kinase KinasesEstrogensSodium-Iodide SymportersTamoxifen

Stichwörter der Autor:innen

estrogen-related receptor gammaradioiodine therapyradioiodine uptakeradioiodine-refractory papillary thyroid cancer cellssodium iodide symporter

Substanzen

Iodine RadioisotopesIodidesMitogensSymportersMitogen-Activated Protein KinasesMitogen-Activated Protein Kinase KinasesEstrogensSodium-Iodide SymportersIodine-131GSK5182

Autor:innen und Institutionen

  • Department of Medical Oncology Lab, All India Institute of Medical Sciences (AIIMS), New Delhi 110029, India.
  • Preclincial Research Center (PRL), Daegu-Gyeongbuk Medical Innovation Foundation (K-MEDI hub), Daegu 41061, Republic of Korea.
  • Department of Pathology, All India Institute of Medical Sciences (AIIMS), New Delhi 110029, India.

ORCID-Profile: Vijaya Sarangthem

Förderung

  • Science & Engineering Research Board (SERB), India
  • Department of Health Research (DHR), India
  • Intramural Research
  • National Research Foundation of Korea (NRF)
  • Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI)
  • Ministry of Health & Welfare, Republic of Korea

Zitieren

APA

Singh, T. D., Lee, J. E., Son, K. H., Lee, B. R., Kim, S. K., Gulwani, D., Sarangthem, V., & Jeon, Y. H. (2023). An Inverse Agonist of Estrogen-Related Receptor Gamma, GSK5182, Enhances Na+/I− Symporter Function in Radioiodine-Refractory Papillary Thyroid Cancer Cells. Cells. https://doi.org/10.3390/cells12030470

Vancouver

Singh TD, Lee JE, Son KH, Lee BR, Kim SK, Gulwani D, et al. An Inverse Agonist of Estrogen-Related Receptor Gamma, GSK5182, Enhances Na+/I− Symporter Function in Radioiodine-Refractory Papillary Thyroid Cancer Cells. Cells. 2023. doi:10.3390/cells12030470

BibTeX
@article{Singh2023,
  author = {Singh, Thoudam Debraj and Lee, Jae Eon and Son, Kwang Hee and Lee, Bo Ra and Kim, Sang Kyoon and Gulwani, Deepak and Sarangthem, Vijaya and Jeon, Yong Hyun},
  title = {An Inverse Agonist of Estrogen-Related Receptor Gamma, GSK5182, Enhances Na+/I− Symporter Function in Radioiodine-Refractory Papillary Thyroid Cancer Cells},
  journal = {Cells},
  year = {2023},
  doi = {10.3390/cells12030470}
}
Kostenlos starten →